Literature DB >> 10954102

Current trends in the management of adamantinoma of long bones. An international study.

A A Qureshi1, S Shott, B A Mallin, S Gitelis.   

Abstract

BACKGROUND: Adamantinoma of long bones is a rare tumor. Published reviews of the orthopaedic management of adamantinoma have involved limited follow-up of small numbers of patients. The oncological aggressiveness of this tumor is unknown. Limb salvage is currently the treatment of choice for most adamantinomas. The purpose of this study was to evaluate the characteristics of adamantinoma of long bones as well as the oncological outcome and the complications of limb salvage operations.
METHODS: A retrospective study was designed to evaluate the clinical outcomes of limb salvage operations for the treatment of adamantinoma. Data on seventy biopsy-proven cases of adamantinoma treated between 1982 and 1992 at twenty-three different cancer centers in Europe and North America were obtained.
RESULTS: The median duration of follow-up was 7.0 years. The male:female ratio was 3:2, and the mean age was thirty-one years. Limb salvage was attempted in 91 percent (sixty-four) of the seventy patients, and the final rate of limb preservation was 84 percent (fifty-nine of seventy). Wide operative margins were obtained in 92 percent (fifty-eight) of sixty-three patients. An intercalary allograft was used to reconstruct the segmental bone defect in 51 percent (thirty-six) of the seventy patients. Reconstruction-related complications occurred in 48 percent (thirty) of sixty-two patients. Nonunion and fracture were the most common complications, occurring in 24 percent (fifteen) and 23 percent (fourteen) of sixty-two patients, respectively. Kaplan-Meier analysis demonstrated a rate of local recurrence of 18.6 percent at ten years. Wide operative margins were associated with a lower rate of local recurrence than marginal or intralesional margins were (p < 0.00005). Kaplan-Meier analysis showed a survival rate of 87.2 percent at ten years. There were no significant relationships between survival and the stage of the tumor (p = 0.058), duration of symptoms (p = 0.90), gender (p = 0.79), or wide operative margins (p = 0.14).
CONCLUSIONS: Current treatment of adamantinoma, including en bloc tumor resection with wide operative margins and limb salvage, provides lower rates of local recurrence than has been previously reported. In the present study, the limb preservation rate was 84 percent (fifty-nine of seventy), and the survival rate was 87.2 percent at ten years. The rate of complications related to the limb reconstruction was high.

Entities:  

Mesh:

Year:  2000        PMID: 10954102     DOI: 10.2106/00004623-200008000-00009

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  26 in total

Review 1.  Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma.

Authors:  Leonard B Kahn
Journal:  Skeletal Radiol       Date:  2003-03-22       Impact factor: 2.199

2.  Adamantinoma of the tibia and fibula with pulmonary metastasis: an unusual presentation.

Authors:  Chékib Khémiri; Dalila Mrabet; Habiba Mizouni; Imen Abbes; Emna Mnif; Slaheddine Sellami; Hamza Essaddem
Journal:  BMJ Case Rep       Date:  2011-10-16

3.  Adamantinoma of long bones: a long-term follow-up study of 11 cases.

Authors:  Miklós Szendroi; Imre Antal; Gabriella Arató
Journal:  Pathol Oncol Res       Date:  2008-12-02       Impact factor: 3.201

4.  Osteofibrous dysplasia, osteofibrous dysplasia-like adamantinoma and adamantinoma: correlation of radiological imaging features with surgical histology and assessment of the use of radiology in contributing to needle biopsy diagnosis.

Authors:  Monica Khanna; David Delaney; Roberto Tirabosco; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2008-08-09       Impact factor: 2.199

Review 5.  Total tibia replacement using an allograft (in a patient with adamantinoma). Case report and review of literature.

Authors:  Sönke P Frey; Jendrik Hardes; Helmut Ahrens; Winfried Winkelmann; Georg Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-30       Impact factor: 4.553

6.  Primary adamantinoma of the rib. Unusual presentation for a bone neoplasm of uncertain origin.

Authors:  Sergio Piña-Oviedo; Luis Del Valle; Rafael Padilla-Longoria; Hilda Mendoza-Ramón; Carlos Ortiz-Hidalgo
Journal:  Pathol Oncol Res       Date:  2008-04-12       Impact factor: 3.201

7.  Adamantinoma: an unusual bone tumour.

Authors:  Pedro Roque; Henry J Mankin; Andrew Rosenberg
Journal:  Chir Organi Mov       Date:  2008-11-15

8.  Adamantinomatous tumors: Long-term follow-up study of 20 patients treated at a single institution.

Authors:  Eugenia Schwarzkopf; Yoely Tavarez; John H Healey; Meera Hameed; Daniel E Prince
Journal:  J Surg Oncol       Date:  2020-04-25       Impact factor: 3.454

Review 9.  Adamantinoma: An Updated Review.

Authors:  Dimitrios N Varvarousis; Georgios P Skandalakis; Alexandra Barbouti; Georgios Papathanakos; Panagiotis Filis; Kostas Tepelenis; Aikaterini Kitsouli; Panagiotis Kanavaros; Panagiotis Kitsoulis
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

10.  Clonality assessment in a case of multifocal adamantinoma and a review of the literature.

Authors:  Paul Borbas; Andreas Leithner; Patrick Sadoghi; Anne Berndt; Bernadette Liegl; Oskar A Haas
Journal:  Case Rep Med       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.